| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 629 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | ELVN Enliven Therapeutics, Inc. | Orbimed Advisors LLC67 | 10% Owner | Sell | 281,408 | $45.02 | $12,668,988.16 | -3.6% | - | - | |
| Jun 15, 2026 | VRTX Vertex Pharmaceuticals Incorporated | Bozic Carmen53 | EVP And CMO | Sell | 4,062 | $450.00 | $1,827,900.00 | -19.3% | - | - | |
| Jun 15, 2026 | NKTR Nektar Therapeutics | Zalevsky Jonathan63 | Chief R&D Officer | Sell | 5,538 | $60.71 | $336,211.98 | -26.4% | - | - | |
| Jun 15, 2026 | KROS Keros Therapeutics, Inc. | Bienaime Jean Jacques68 | Director | Buy | 1,000 | $10.19 | $10,190.00 | +6.0% | - | - | |
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Goodrich Katherine | Director | Sell | 2,954 | $62.08 | $183,384.32 | -57.0% | - | - | |
| Jun 15, 2026 | OCGN Ocugen, Inc. | Johnson-Greene Treerita Essalima | Chief Financial Officer | Buy | 21,000 | $1.23 | $25,830.00 | +4.2% | - | - | |
| Jun 15, 2026 | QURE Uniqure N.V. | Potts Jeannette | Chief Legal Officer | Sell | 5,237 | $27.67 | $144,907.79 | -3.8% | - | - | |
| Jun 15, 2026 | XNCR Xencor, Inc. | Gorman Kevin Charles55 | Director | Sell | 7,527 | $12.31 | $92,657.37 | -39.8% | - | - | |
| Jun 15, 2026 | CTMX Cytomx Therapeutics, Inc. | Ogden Christopher50 | Chief Financial Officer | Sell | 1,624 | $3.05 | $4,953.20 | -0.5% | - | - | |
| Jun 15, 2026 | IMNM Immunome, Inc. | Rosett Max | Chief Financial Officer | Sell | 60,000 | $18.23 | $1,093,800.00 | -52.6% | - | - | |
| Jun 15, 2026 | JAZZ Jazz Pharmaceuticals Plc | Smith Mark Douglas68 | Director | Sell | 1,157 | $230.55 | $266,746.35 | -10.7% | - | - | |
| Jun 15, 2026 | XNCR Xencor, Inc. | Ranieri Richard J | Director | Sell | 5,474 | $12.31 | $67,384.94 | -28.5% | - | - | |
| Jun 15, 2026 | ARDX Ardelyx, Inc. | Raab Michael56 | President &CEO | Sell | 41,666 | $5.67 | $236,346.22 | -2.4% | - | - | |
| Jun 15, 2026 | CMND Clearmind Medicine Inc. | Hrt Financial LP45 | 10% Owner | Sell | 3,183 | $3.32 | $10,567.56 | -3.0% | - | - | |
| Jun 15, 2026 | ADTX Aditxt, Inc. | Hrt Financial LP45 | 10% Owner | Buy | 2,114,344 | $0.01 | $29,600.82 | -119.5% | - | - | |
| Jun 12, 2026 | SPRY Ars Pharmaceuticals, Inc. | Fitzpatrick Alexander A81 | Chief Legal Officer | Sell | 3,355 | $10.00 | $33,550.00 | -3.6% | - | - | |
| Jun 12, 2026 | IONS Ionis Pharmaceuticals, Inc. | Kordasiewicz Holly B. | EVP, Chief Development Officer | Sell | 60,846 | $73.41 | $4,466,427.83 | -48.4% | - | - | |
| Jun 12, 2026 | SMMT Summit Therapeutics Inc. | Zanganeh Mahkam84 | Co-chief Executive Officer | Buy | 3,810,000 | $13.12 | $49,987,200.00 | +0.7% | - | - | |
| Jun 12, 2026 | SPRY Ars Pharmaceuticals, Inc. | Karas Eric76 | Chief Commercial Officer | Sell | 25,000 | $10.00 | $250,000.00 | -67.2% | - | - | |
| Jun 12, 2026 | SEPN Septerna, Inc. | Shaikhly Samira | Chief People Officer | Sell | 6,250 | $35.08 | $219,224.37 | -88.7% | - | - | |
| Jun 12, 2026 | SER Serina Therapeutics, Inc. | Wilson Karen J | Director | Buy | 10,100 | $1.76 | $17,749.50 | +198.0% | - | - | |
| Jun 11, 2026 | CDXS Codexis, Inc. | De Vre Raymond | Director | Sell | 2,605 | $2.37 | $6,173.85 | -3.0% | - | - | |
| Jun 11, 2026 | PBLS Parabilis Medicines, Inc. Common Stock | Sebulsky Alan | Director | Buy | 12,500 | $20.00 | $250,000.00 | New | - | - | |
| Jun 11, 2026 | PTHS Pelthos Therapeutics Inc. | Davis Todd C78 | Director | Buy | 35,948 | $27.82 | $999,983.28 | +31.2% | - | - | |
| Jun 11, 2026 | CRVO Cervomed Inc. | Boger Joshua S | Director, 10% Owner | Buy | 955,414 | $3.14 | $2,999,999.96 | +113.7% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.